FDA
-
-
-
-
-
-
-
Synthetic Biologics (SYN) Announces Extension of Compliance Plan Period by NYSE American
-
-
-
-
-
-
-
Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients
-
-
-
-
-
-
-
Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results
-
-
-
-
-
-
-
Synthetic Biologics (SYN) Reports In-Line Q2 EPS
-
-
-
-
-
-
-
Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development
-
-
-
-
-
-
-
Synthetic Biologics (SYN) Announces 1-for-35 Reverse Stock Split
-
-
-
-
-
-
-
Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results
-
322,946 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

